Cipla Limited
Cipla Limited (India) holds 166 active US FDA Type II Drug Master Files and 119 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 2 active Type IV (excipient) Drug Master Files and is linked to 6 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Cipla Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/cipla-limited
Overview
Cipla Limited is a global pharmaceutical company based in India focused on developing, manufacturing, and distributing a wide range of medications. The company specializes in therapies for various medical conditions, ensuring access to affordable medicines for patients worldwide.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Cipla Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Cipla Limited holds 166 active (285 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- TROFINETIDE (C)Active2026-08-19
- TERLIPRESSIN ACETATEActive2026-04-15
- RESMETIROM (C)Active2026-03-26
- TROFINETIDEActive2026-03-21
- RIBOCICLIB SUCCINATEActive2026-03-18
- UMECLIDINIUM BROMIDEActive2026-03-12
- ZAVEGEPANT HYDROCHLORIDEActive2026-03-06
- ETRASIMOD ARGININEActive2026-03-03
- LENACAPAVIR SODIUMActive2026-02-03
- ENSIFENTRINE (C)Active2025-11-26
- CALCIUM GLUCONATE MONOHYDRATE USPActive2025-11-25
- ABEMACICLIBActive2025-10-31
- GLYCOPYRROLATE USPActive2025-09-30
- IXAZOMIB CITRATEActive2025-08-13
- DIBASIC POTASSIUM PHOSPHATE USPActive2025-08-10
- DEUCRAVACITINIBActive2025-03-28
- MONOBASIC POTASSIUM PHOSPHATE NFActive2025-03-28
- MOMETASONE FUROATE USPActive2025-03-28
- ENSIFENTRINEActive2025-03-25
- NIRAPARIB TOSYLATE MONOHYDRATEActive2025-03-21
- RESMETIROMActive2025-02-28
- DAPRODUSTATActive2025-01-31
- DARUNAVIR HYDRATE (PROCESS II)Active2025-01-10
- OMEPRAZOLE USP PROCESS-IIActive2024-12-31
- APIXABANActive2024-12-30
- RELUGOLIXActive2024-03-29
- IVACAFTORActive2024-02-16
- VILANTEROL TRIFENATATEActive2024-02-11
- POMALIDOMIDEActive2023-12-20
- ISAVUCONAZONIUM SULFATEActive2023-12-18
- DASATINIB MONOHYDRATEActive2023-11-30
- ESCITALOPRAM OXALATE USP (PROCESS-II)Active2023-10-12
- BREXPIPRAZOLEActive2023-07-20
- ACALABRUTINIB MALEATEActive2023-07-14
- RUXOLITINIB PHOSPHATEActive2023-07-13
- CITALOPRAM HYDROBROMIDE USPActive2023-03-29
- CABOTEGRAVIRActive2023-03-20
- RILPIVIRINEActive2023-03-16
- SORAFENIB TOSYLATE USPActive2023-02-28
- CABOTEGRAVIR SODIUMActive2023-02-27
- DIFELIKEFALIN ACETATEActive2023-01-25
- NIRMATRELVIRActive2023-01-18
- ABIRATERONE ACETATE USPActive2023-01-14
- TAFAMIDIS (I)Active2022-12-28
- TAFAMIDISActive2022-11-28
- SIPONIMOD ADIPIC ACIDActive2022-11-17
- TENOFOVIR ALAFENAMIDE MONOFUMARATEActive2022-09-27
- OLAPARIBActive2022-08-01
- INDACATEROL ACETATEActive2022-05-13
- REVEFENACINActive2022-05-06
Showing the 50 most relevant of 285 Drug Master Files (active first). The full list is in the FDA DMF list.
Excipient Drug Master Files
Cipla Limited holds 2 active (2 total) FDA Type IV Drug Master Files. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- N-DODECYL-BETA-D-MALTOSIDEActive2024-10-17
- SALCAPROZATE SODIUMActive2024-10-10
Registered manufacturing sites (6)
Physical sites registered with the US FDA and resolved to Cipla Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- CIPLA LIMITEDIndore, India · Analytical testing · Labelling
- CIPLA LIMITEDSalcette, India · Analytical testing · LabellingSite GMP match
- CIPLA LIMITEDPune, India · API manufactureSite GMP match
- CIPLA LIMITEDBengaluru, India · API manufacture
- CIPLA LIMITEDBengaluru, India · API manufactureSite GMP match
- CIPLA LIMITEDRaigad, India · API manufacture
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2025-12-10
Failed Stability Specifications: Observed OOS results: eg results for colour index
- 4832024-06-21
Computer control of master formula records
- 4832024-06-21
Investigations of discrepancies, failures
- 4832024-06-21
Environmental Monitoring System
- 4832024-06-21
Test methods
- 4832024-06-21
Procedures not in writing, fully followed
- 4832024-06-21
Cleaning System
- warning_letter2023-11-17
FDA Warning Letter (drug product)
- recall — Class II2022-10-12
Lack of Assurance of Sterility: environmental monitoring failure.
- recall — Class II2022-10-05
Lack of Assurance of Sterility
- recall — Class II2022-09-14
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
- recall — Class II2022-09-14
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
- 4832022-08-26
Procedures not in writing, fully followed
- 4832022-08-26
Cleaning System
- 4832022-08-26
Environmental Monitoring System
- 4832022-08-26
Cleaning SOPs/schedules
- 4832022-08-26
Validation lacking for sterile drug products
- 4832022-08-26
Computer control of master formula records
- recall — Class II2022-08-17
Lack of Assurance of Sterility: Complaints received of defective container closure.
- recall — Class II2022-07-27
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
- recall — Class II2021-07-21
CGMP Deviations
- recall — Class II2021-01-06
Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline
- recall — Class II2021-01-06
Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline
- recall — Class II2021-01-06
Cross- contamination with other products: The excipient, Crospovidone, NF is contaminated with theophylline
- recall — Class II2020-12-23
cGMP deviations: Vials may not be sealed correctly affecting sterility.
- warning_letter2020-02-12
FDA Warning Letter (drug product)
- 4832019-09-27
Investigations of discrepancies, failures
- 4832019-09-27
Absence of Written Procedures
- 4832019-09-27
Equipment Design, Size and Location
- 4832019-09-27
Equipment to control conditions
- 4832019-09-27
Validation lacking for sterile drug products
- 4832019-09-27
Equipment for Environmental Control
- 4832019-09-27
Approval and review of procedures
- 4832019-09-27
Procedures for sterile drug products
- 4832019-09-27
Buildings of Suitable Size, Construction, Location
- 4832019-09-27
Sampling/testing of in-process materials
- 4832019-09-27
Cleaning / Sanitizing / Maintenance
- 4832019-09-27
Written procedures not established/followed
- recall — Class II2018-12-26
Failed Dissolution Specifications.
- 4832017-12-06
Results of drug product inspections and examinations
- 4832017-12-06
Extent of discrepancy, failure investigations
- 4832017-12-06
Investigations of discrepancies, failures
- 4832017-12-06
Procedures not in writing, fully followed
- 4832017-12-06
Written program not followed
- 4832017-12-06
Complaint Handling Procedure
- 4832017-12-06
Training , Education , Experience overall
- 4832017-12-06
Following/documenting laboratory controls
- 4832017-12-06
SOPs not followed / documented
- recall — Class III2015-05-20
Failed Impurities/Degradation Specifications: Product is out of specification for a known degradant.
- 4832014-06-25
Timely submission
Is this Cipla Limited?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.